LFSC Fact Sheet: F/m Emerald Life Sciences Innovation ETF
Share
$41.58
close, Nov 20, 2026
Over the year to Nov 19, 2026, LFSC returned +24.6% in total and charged 0.54% a year.
- 1-year total return
- +23.1%
- IWV +7.4% to Nov 20, 2026
- Expense ratio
- 0.54%
- a year
- Net flow, 12 months to Aug 31, 2026
- +$16.2m
- monthly N-PORT basis to Aug 31, 2026
Growth of $10,000, 1 year
LFSC $12,461 +24.6% · IWV $10,940 +9.4% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−2.4%
3 months−13.0%
Year to date+13.5%
1 year+23.1%
Since launch+67.0%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Travere Therapeutics Inc8.71%
Corcept Therapeutics Inc6.72%
Spyre Therapeutics Inc6.70%
LivaNova PLC6.61%
Cogent Biosciences Inc6.48%
Mirum Pharmaceuticals Inc4.32%
Billiontoone Inc3.86%
Guardant Health Inc3.81%
Cytokinetics Inc3.50%
United Therapeutics Corp3.27%
LFSC top ten by weight, 54.0% of the fund, of its 37 equity positions, from the holdings filed for Aug 31, 2026.
Facts
Holds 38 stocks in broad innovation and megatrends, 0% of its weight in S&P 500 companies · First traded Oct 31, 2024 · Benchmark Russell 3000 Total Return Index, measured by IWV, which tracks the same index